Purchase Order 75N94021P00837
Award Date 9/7/21
Potential Completion Date 9/7/22
Potential Value $105K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Temple City, CA 91780, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
3
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a definitive contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, for SARS-COV-2 genomic sequencing services. The firm fixed price contract has a potential value of $40,517,395.00 and a completion date of March 10, 2022. Fulgent Diagnostics is a division of Fulgent Genetics, Inc. and has provided genetic and genomic testing services to various federal agencies,...
- This federal contract award was issued by the Department of Veterans Affairs Veterans Health Administration to Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, a provider of genomic testing services and COVID-19 testing kits and services to U.S. federal government agencies. The contract is for germline genetic testing with a potential value of $150,000.00 and is a Firm Fixed Price BPA Call order. Fulgent Therapeutics holds a separate $950,000.00 Blanket Purchase Agreement from...
- This is a firm fixed price contract awarded by the Department of Veterans Affairs (VA) to Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, for germline genetic testing services. The contract has a ceiling value of $95,817.89 and a period of performance through September 30, 2018. It was awarded as a total small business set-aside. Fulgent Diagnostics is a provider of genomic testing services and COVID-19 testing kits and services to various federal agencies, including the VA,...
- This federal contract award to Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, is a $935,715 firm fixed price purchase order for NEXT GEN TESTING AT MAMC, awarded by the U.S. Army Medical Command. The contract has a period of performance through September 30, 2019 and does not have a set-aside designation. Fulgent Therapeutics is a subsidiary of Fulgent Genetics, Inc., a provider of comprehensive genomic testing services to various federal agencies including the Department of...
- Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, received a $4.34 million firm fixed price purchase order from the Department of Veterans Affairs Strategic Acquisition Center Frederick on September 27, 2022, for germline genetic testing services. The contract will be performed in Temple City, California, and is scheduled for completion by September 26, 2025. This award was issued without a set-aside designation, indicating open competition. The purchase order supports the VA's...
- The Department of Veterans Affairs Strategic Acquisition Center Frederick awarded a $2.949 million delivery order for germline pharmacogenomic molecular testing to Fulgent Therapeutics LLC (doing business as Fulgent Diagnostics) on September 30, 2024. This supplemental agreement represents work within scope and is issued without a set-aside designation, indicating open competition. The work will be performed in Frederick, Maryland, with an ultimate completion date of September 29, 2029. This...
- This is a $6,573,600 Indefinite Delivery/Indefinite Quantity (IDIQ) contract awarded by the U.S. Department of Veterans Affairs (VA) Strategic Acquisition Center-Frederick to Fulgent Therapeutics LLC, a subsidiary of Fulgent Genetics, Inc. The contract is for germline genetic testing services in support of the VA's National Oncology Program (NOP) and has a period of performance through September 29, 2029. This contract is not designated as a set-aside. Fulgent Therapeutics is an experienced...
- This contract was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency within the U.S. Department of Health and Human Services, to Transnetyx, Inc., a for-profit organization specializing in advanced genetic testing and analysis services. The $8,382.75 Firm Fixed Price contract is a Blanket Purchase Agreement (BPA) call, with a period of performance running through September 10, 2025. Transnetyx has established itself as a critical provider...
- The Department of Health and Human Services National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded a $201,059.24 firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of genomics analysis instruments and reagents, for an annual NextSeq 550 sequencing instrument service plan. The contract has a base year from April 30, 2022 to April 29, 2023 with four one-year option periods. Illumina is the sole authorized service provider...
- The Department of Health and Human Services' National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a firm fixed-price delivery order contract to Illumina, Inc., a for-profit manufacturer of sequencing and genomics analysis equipment. The $193,926.00 contract, which has a completion date of September 2, 2025, is for the provision of consumables to support NIDDK's research and diagnostic activities. Illumina has a history of federal contract...